Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
glimeryl tafla 1 mg
teva b.v.* - glimepiride - tafla - 1 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
glimeryl tafla 2 mg
teva b.v.* - glimepiride - tafla - 2 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
glimeryl tafla 3 mg
teva b.v.* - glimepiride - tafla - 3 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
glimeryl tafla 4 mg
teva b.v.* - glimepiride - tafla - 4 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
methotrexat ebewe innrennslisþykkni, lausn 100 mg/ml
ebewe pharma ges.m.b.h.nfg. kg - methotrexatum inn - innrennslisþykkni, lausn - 100 mg/ml
Evrópusambandið -
íslenska -
EMA (European Medicines Agency)
tandemact
cheplapharm arzneimittel gmbh - lyfleysu, glimepiride - sykursýki, tegund 2 - lyf notuð við sykursýki - tandemact er ætlað fyrir sjúklinga með tegund-2 sykursýki sem sýna óþol að kvarta eða fyrir hvern kvarta er ekki ætlað og hver ert nú þegar meðhöndluð með sambland af lyfleysu og glimepiride.
Evrópusambandið -
íslenska -
EMA (European Medicines Agency)
spikevax (previously covid-19 vaccine moderna)
moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - bóluefni - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
marcain stungulyf, lausn 2,5 mg/ml
aspen pharma trading limited - bupivacainum hýdróklóríð - stungulyf, lausn - 2,5 mg/ml
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
marcain stungulyf, lausn 5 mg/ml
aspen pharma trading limited - bupivacainum hýdróklóríð - stungulyf, lausn - 5 mg/ml